Milestone Scientific

Milestone Scientific, Inc. is a biomedical technology research and development company, which patents, designs, and develops diagnostic and therapeutic injection technologies and instruments. It operates through the following segments: Dental, Medical, and Corporate. The Corporate segment refers to executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities, and public company compliance costs. Its solutions include CompuFlo Epidural, CathCheck Verification System, and Single Tooth Anesthesia System. The company was founded on August 17, 1989 and is headquartered in Roseland, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Milestone Scientific reports Q1 revenue, eyes international expansion opportunities

Milestone Scientific's Q1 2024 performance showed revenue over $2.2 million with improved gross margins.
The company's focus on customer relationships and reimbursement strategies is a key strength.
Challenges include revenue decrease and the need for endorsements in the medical space.
Opportunities lie in international expansion, market penetration goals, and increased marketing efforts.

Milestone Scientific reports improved Q2 performance amidst revenue challenges

Milestone Scientific showcased financial improvements in Q2 2024 despite a revenue decrease, with a focus on enhancing operational efficiency and achieving positive cash flow.
The company's strategic partnerships, international expansion plans, and commitment to innovation through intellectual property enhancements signal a path for future growth and market competitiveness.
While facing challenges in revenue generation and operational clarity, Milestone Scientific's strong balance sheet and market positioning offer opportunities for sustained growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Milestone Scientific, Inc. (MLSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Milestone Scientific, Inc. (MLSS) Moves to Buy: Rationale Behind the Upgrade

Milestone Scientific Inc (NYSE:MLSS) is boosting its medical sales team with the appointment of Chet Trechock as vice president of sales medical along with three new representatives. Trechock has over 25 years of experience in the medical sales industry focusing on pain management, neurosurgery, neurology and orthopedics.

Milestone Scientific expands sales team to capitalize on interest in CompuFlo and CathCheck medical devices

ROSELAND, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has expanded its medical sales team including the appointment of Chet Trechock as VP of Sales Medical.

Milestone Scientific Expands Medical Sales Team to Capitalize on Growing Interest in CompuFlo Including Appointment of Senior Industry Sales Executive Chet Trechock as VP of Sales for Medical

ROSELAND, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug instruments that provide painless and precise injections, has been invited to present at the "Summer Solstice – Best Ideas from the Buy-Side" conference, which is being held virtually on June 1st – 4th, 2021.

Milestone Scientific to Participate in the Summer Solstice Conference - Best Ideas from the Buy-Side on June 2nd

Revolutionizing injections for doctors and patients CompuFlo instruments provide feedback to distinguish tissue types for precise location guidance Establishing relationships with world-class global partners What Milestone Scientific Inc does: Milestone Scientific Inc (NYSEAMERICAN:MLSS) is a medical device research and development (R&D) group. It designs and patents innovative injection technology and specializes in dynamic pressure sensing, which allows medics to know what the pressure at the tip of needle is at any time.

Milestone Scientific, the pressure sensing medtech group, enjoying revenue and cash flow growth

Milestone Scientific Inc. (MLSS) Q1 2021 Results - Earnings Call Transcript

Milestone Scientific Inc (NYSE:MLSS) reports that first-quarter revenue increased by double-digits year-over-year as the company commercializes its CompuFlo Epidural System.  The company also announced that it closed the quarter ended March 31 with about $17 million in cash and cash equivalents -- a substantial runway that will allow Milestone Scientific to accelerate its sales and marketing activities around its dental and medical instruments.

Milestone Scientific reports double-digit, year-over-year increase in 1Q revenue

Milestone Scientific, Inc. (MLSS) delivered earnings and revenue surprises of 66.67% and -37.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Milestone Scientific, Inc. (MLSS) Reports Q1 Loss, Misses Revenue Estimates

Achieves 32% sequential increase in revenue for Q1 2021 versus Q4 2020

Milestone Scientific Reports a 61% Increase in Revenue for Q1 2021

Milestone Scientific Inc (NYSEAMERICAN:MLSS) has announced the promotion of company president Jan Adriaan (Arjan) Haverhals to be its new chief executive officer (CEO) after Leonard Osser said he intends to step down as the company's interim CEO. Milestone Scientific also said it has appointed Scott Kahn as its new chief financial officer (CFO) effective May 24, succeeding Joseph D'Agostino who retired from the company last month.

Milestone Scientific promotes its president Arjan Haverhals to the position of CEO

Milestone Scientific Announces Promotion of Arjan Haverhals to CEO

ROSELAND, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it will host a conference call at 11:00 A.M. Eastern Time on Monday, May 17, 2021 to discuss the Company's financial results for the first quarter ended March 31, 2021, as well as the Company's corporate progress and other developments.

Milestone Scientific Schedules First Quarter 2021 Business Update Conference Call

American Shared Hospital Services

Precipio

TOP Ships

Looking for penny stocks to watch in May? Look no further The post 4 Hot Penny Stocks To Watch In May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Hot Penny Stocks To Watch In May 2021

The stock price of Milestone Scientific Inc. (NYSEAMERICAN: MLSS) increased from $2.52 to $3.17 (up 25.79%) during intraday trading this morning. This is why it happened.

MLSS Stock: From $2.52 To $3.17 (25.79% Increase) Explanation

ROSELAND, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced preliminary financial results for the first quarter of 2021.

Milestone Scientific Reports Preliminary Sales Results for Q1 2021; Revenue Increases 61% Over the Same Period Last Year

Milestone Scientific's (MLSS) CEO Leonard Osser on Q4 2020 Results - Earnings Call Transcript

Milestone Scientific Inc (NYSEAMERICAN:MLSS) posted fourth-quarter results on Thursday that saw its revenue rocket 78%, compared to the third quarter thanks to its growing dental business and flourishing distribution network. For the period ended December 31, 2020, the Roseland, New Jersey-based developer of computerized drug delivery instruments that provide painless and precise injections, reported a $1 million, or 78% sequential gain in revenue, compared to the third quarter of 2020.

Milestone Scientific sees a 78% sequential rise in 4Q revenue powered by its dental business

Milestone Scientific Reports Continued Progress on Commercial Rollout of CompuFlo Epidural System Milestone Scientific Reports Continued Progress on Commercial Rollout of CompuFlo Epidural System

Milestone Scientific Provides 2020 Year-End Business Update; Reports a 78% Sequential Increase in Revenue for Q4 2020 Versus Q3 2020

ROSELAND, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 1, 2021 to discuss the Company's financial results for the full year ending December 31, 2020, as well as the Company's corporate progress and other developments.

Milestone Scientific Schedules 2020 Year-End Business Update Conference Call

Milestone Scientific, Inc. (MLSS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Milestone Scientific, Inc. (MLSS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

ROSELAND, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced that Arjan Haverhals, CEO of Wand Dental and President of Milestone Scientific, will be presenting at the Q1 Virtual Investor Summit on March 24th.

Milestone Scientific to Present at the Q1 Virtual Investor Summit

Milestone Scientific Inc (NYSEAMERICAN:MLSS) announced Wednesday it has received a Notice of Allowance from the European Patent Office as the company seeks to develop a device for ultrasound-guided peripheral nerve block (PNB) procedures. The patent office's decision allows for the company to combine minimum intensity of nerve stimulation (MIS) and real-time injection pressure (IP) monitoring by utilizing Milestone's CompuFlo instrument and associated DPS Dynamic Pressure Sensing Technology to optimize needle tip location in PNB procedures.

Milestone Scientific receives notice of allowance for European patent as company seeks to develop device for ultrasound-guided peripheral nerve block procedures

ROSELAND, N.J., March 10, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it has received Notice of Allowance from the European Patent Office (EPO) combining minimum intensity of nerve stimulation (MIS) and real-time injection pressure (IP) monitoring utilizing Milestone's CompuFlo® instrument and associated DPS Dynamic Pressure Sensing Technology® to optimize needle tip location in ultrasound-guided peripheral nerve block (PNB) procedures. The technology was developed in conjunction with Dr. Olivier Choquet from the Lapeyronie University Hospital Montpellier France, a renowned expert in peripheral nerve block procedures, and Dr. Mark Hochman, D.D.S., Inventor and Clinical Director for Milestone Scientific.

Milestone Scientific Receives Notice of Allowance for European Patent Related to Combination of Nerve Stimulation and DPS Dynamic Pressure Sensing Technology® to Optimize Needle Tip Location in Ultrasound-Guided PNB Procedures

Milestone Scientific Inc (NYSEAMERICAN:MLSS), a leading developer of computerized drug delivery instruments that provide virtually painless and precise injections, said Tuesday it has begun selling CompuFlo/CathCheck disposables to the Medical University of South Carolina (MUSC).  The MUSC University Medical Center is a nationally recognized and leading health sciences university, recently ranked as the number one hospital in South Carolina, the company noted.

Milestone Scientific starts selling CompuFlo/CathCheck disposables to the Medical University of South Carolina

ROSELAND, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it has begun selling CompuFlo® / CathCheck™ disposables to the Medical University of South Carolina (MUSC). The MUSC University Medical Center is a nationally recognized and leading health sciences university, recently ranked as the number one hospital in South Carolina. MUSC Health owns and operates eight hospitals and provides patient care throughout the state of South Carolina.

News for Milestone Scientific Stock (MLSS)